Positive expression levels of the biomarker were more common in adenocarcinoma than in squamous cell carcinoma, among patients who had non–small cell lung cancer (NSCLC). New research has identified a ...

Flaig: It has been a remarkable 10 years for bladder cancer. If you think back to 10 or 15 years ago, we had no new ...

“Together, this work highlights the need to investigate different breakpoints of fusion proteins, as they may potentially lack the necessary biological activity required for oncogenesis, ultimately ...

Vofatamab (B-701) may be safe and effective for patients with locally advanced or metastatic bladder cancer with an FGFR3 mutation who have relapsed after, or are refractory to, at least one prior ...

Tyra Biosciences (TYRA) is gearing up to report data from its phase 1/2 study, using its FGFR3-inhibitor TYRA-300 for the treatment of patients with urothelial carcinoma and solid tumors. In ...

Impact of Variable RNA-Sequencing Depth on Gene Expression Signatures and Target Compound Robustness: Case Study Examining Brain Tumor (Glioma) Disease Progression We correlated somatic FGFR3-TACC3 ...

Credit: Getty Images. TYRA-300 is an investigational, oral, FGFR3-selective inhibitor. The Food and Drug Administration (FDA) has granted Orphan Drug designation to TYRA-300 for the treatment of ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved erdafitinib for certain adults with locally advanced or metastatic urothelial carcinoma. The ...

Several forms of cancer, including bladder cancer and multiple myeloma caused by the t(4;14) genetic abnormality, are associated with either overexpression or perpetual activation of the protein FGFR3 ...

JCO Precision Oncology Conversations features discussions with leading authors of JCO Precision Oncology articles, hosted by Dr. Abdul Rafeh Naqash. Join our experts in engaging conversations as they ...

HAMILTON, ON and BOSTON, Aug. 29, 2022 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as ...